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Abstract. In a prospective randomized double-blind study,
we evaluated the post-operative biological and clinical
effects of a single preoperative hyperbaric-treatment the day
before surgery for pancreatic ductal adenocarcinoma.
Patients and Methods: Twenty one patients were randomized
and divided into two groups: group-A (10 patients, 48%)
were exposed to a HyperBaric Oxygen (HBO) session the
day before intervention [Pre-Intervention Day (PID)], group-
B (11 patients, 52%) breathed air for 40 min in a hyperbaric
chamber pressurized to 1.15 ATA (placebo group). For all
patients blood samples were obtained before HBO treatment
or the placebo procedure (T0); at the end of HBO session or
placebo procedure (T1); on the first post-operative day
(POD)(T2) and on seventh POD(T3) day, measuring
interleukin (IL)-1, IL-6, IL-8, IL-10, IL-12 and TNF-α,
recording postoperative pancreatic fistula (POPF), biliary-
fistula, fever, intra-abdominal abscess, bleeding, pulmonary
complications, delayed gastric emptying and requirement for
post-operative antibiotics. The results of the present pilot
study suggest that a single preoperative hyperbaric oxygen
treatment on the day before surgery may reduce the
complication rate in pancreatic resection.
Hyperbaric oxygen (HBO) therapy involves the intermittent
inhalation of 100% oxygen in chambers pressurized between
1.5 and 3.0 atmosphere absolute (ATA) (3). HBO increases
both dissolved oxygen and the partial pressure of oxygen in
plasma (4, 22). HBO is commonly used in the treatment of
decompression sickness, carbon monoxide intoxication,
arterial gas embolism, necrotizing soft tissue infections,
chronic skin ulcers, severe multiple trauma with ischemia
and ischemic diabetic foot ulcers (3-14). A possible
mechanism of HBO mediating beneficial effects has been
described as attenuation of the production of pro-
inflammatory cytokines in response to an inflammatory
stimulus such as surgery (15, 38) and modulation of the
immune response (3, 5). Previous data by Yang and
colleagues on animals demonstrated that HBO inhibits TNF-
α production during intestinal ischemia-reperfusion (30) and
it has a beneficial effect, mediated by decreased production
of both TNF-α and IL-1β, on indomethacin-induced
enteropathy (31). The positive role of HBO in human surgery
has been demonstrated in cardiovascular (16, 17), orthopedic
surgery (18), and after liver transplantation, as reported by
Franchello et al. which documented a reduction of ischemic
areas and an increase of intrahepatic arterial vascularisation
by collateral vessels after 20 HBO sessions in a patient
affected by Hepatic Artery Thrombosis (HAT) after liver
transplantation (19). Pancreatico-duodenectomy (PD) is
associated with a significant complication rate ranging
between 30%-60% (20), often with prolonged hospital stay
and economic resource utilization (21). 
The main objective of the present pilot study on patients
receiving PD was to identify differences between the
concentration of inflammatory cytokines in two groups of
patients exposed to HBO or sham prior to PD procedure. A
secondary objective was assessment and comparison of the
complication rate and duration of hospital stay between the
two groups.
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Patients and Methods
Ethics approval was obtained from local regional ethics committee
of the University of Verona, Italy (n. 2176/2012). The study was a
prospective, randomized double-blind study lasting 6 months.
Patients were randomized at the Hyperbaric Institute SpA of
Villafranca (Verona, Italy) by gaining exposure to HBO treatment,
using a computer-generated allocation schedule and were divided
into two groups. Twenty-four hours before the planned PD, patients
of group "A" were submitted to a HBO session, while Patients of
group "B" breathed air in a multiplace hyperbaric chamber
pressurized to 1.15 ATA (sham).
All patients received medical evaluation to exclude absolute
contraindications to hyperbaric therapy, including electrocardio-
graphy, thoracic X-Ray and the count of white cells, red cells,
haemoglobin and hematocrit. Patients aged >80 years or <18 years,
or affected by cavitary or current tuberculosis, bronchiectasis, lung
abscess, previous spontaneous pneumothorax or traumatic current not
already drained, heart failure, pulmonary edema, acute purulent
sinusitis, severe glaucoma, hypercapnic respiratory insufficiency with
pCO2 >60 mmHg, previous rupture of inner ear’s round or oval
membrane, sinus bradycardia, inflammation of the upper respiratory
tract, parenchymal or mechanical bronchoconstrictions or epilepsy,
were excluded from the study.
The HBO session was a single hyperbaric exposure at 2.5 ATA
for a duration of 116 min: 12-15 min of compression time, 3 periods
of 24 min each on 100% O2 at maximum pressure, interrupted by
two air breathing periods of 5 min each. Oxygen was delivered to
patients via a tight-fitting mask. Decompression to 1 ATA occurred
over 18 min, with 3 min at 1.3 ATA. Oxygen was administered
starting at 1.6 ATA and during decompression from 2.5 to 1.3 ATA.
During the entire exposure time an experienced hyperbaric-trained
physician was inside the hyperbaric chamber as required by the
practice quality provisions of the Hyperbaric Institute.
In all patients, small venous blood samples were obtained before
(T0) and at the end (T1) of HBO session or placebo procedure; at
the first post-operative day (POD) (T2) and in the seventh POD
(T3). Venous blood samples were collected in heparinized tubes and
the plasma obtained stored at –80˚C. The BDTM CBA Human
Inflammatory Cytokines kit number 551811 (Becton, Dickinson and
Company BD Biosciences San Jose, CA, USA) was used to measure
interleukin (IL)-1, IL-6, IL-8, IL-10, IL-12p70 and TNF-α. The
FCAP ArrayTM software (Becton, Dickinson and Company BD
Biosciences San Jose, CA 95131) was used to generate results in
graphical and tabular format. 
The following postoperative complications were recorded: post-
operative pancreatic fistula (POPF), biliary fistula, fever, intra-
abdominal fluid collections, defined as the presence of fluid collection
of 5 cm in diameter with or without clinical significance at CT scan or
ultrasound presence, bleeding, pulmonary complications, including
pneumonia, bronchospasm, respiratory failure and prolonged
mechanical ventilation delayed gastric emptying, defined as the need
of nasogastric tube decompression for 10 days and the use of
postoperative antibiotics. For the evaluation of the complications we
followed carefully the definition proposed by Bassi et al. (23) and we
classified the POPF using the definition proposed by ISGPF (24).
Pulmonary complications were diagnosed from presence of three of
the following: fever, purulent sputum, tachycardia, tachypnea,
inspiratory crackles, bronchial breathing, abnormal chest x-ray, arterial
hypoxemia, positive stain and culture, as described by Bassi et al. (62).
For statistical analysis, the Chi-squared test after Yates and Fisher
tests, when necessary, were used. All statistical tests were two-sided. A
p-value less than 0.05 indicated statistical significance. All statistical
analyses were performed using the Statistical Package for the Social
Sciences (SPSS) software version 19.0 (SPSS, Chicago, IL). 
Results
From 01-02-2012 to 31-07-2012 in our Department 127
patients underwent pancreatic resection (81 [63.8%] pylorus
preserving pancreatico-duodenectomy [PPPD], 9 [7.1%]
Whipple procedures, 28 [22%] distal pancreatic resections,
7 [5.5%] intermedial pancreatic resections and 2 [1.6%] total
pancreatic resections). Out of these patients, 32 were
recruited to the present study (25.2%) using “geographic
criteria”. In fact, all patients recruited in the study lived near
the Hyperbaric Institute (maximum 150 km) in order to
carry-out the tests and the bureaucracy needed for the HBO
therapy and preconditioning. Out of these patients, 5 (15.6%)
presented a “borderline” neoplasia when the tumor involved
the celiac axis or the superior mesenteric artery (unresectable
primary tumor) at CT scan (Stage III sec. AJCC) and they
were treated with thermoablation, while other 6 (18.8%)
presented liver metastasis (Stage IV sec. AJCC). The
remaining 21 (65.6%) patients presented with resectable
pancreatic cancer. From these last patients, 11 were
randomized to the placebo group (52.4%) and the other 10
(47.6%) to the HBO group. All patients recruited in this
study had a resectable lesion and underwent PPPD. The flow
chart of the randomization is described in Figure 1. 
The results of serum concentrations of IL-1, IL-6, IL-8,
IL-10, TNF-α, IL-12p70 at T0, T1, T2 and T3 are listed
below (Table I). The maximum concentration of cytokines
was at T2. Level of IL-6 was significantly lower in “A”
group, while IL-10 level was significantly higher after HBO
exposure. 
Table I shows the correlation between the age distribution in
placebo group and HBO group, the tumor histology, the
incidence of POPF and biliary fistula, the incidence of fever,
postoperative use of antiobiotics, pulmonary complications,
delayed gastric empty (DGE) and bleeding by group. In the
group of 21 patients that underwent surgical procedure, 14
(66.7%) underwent PPPD for pancreatic ductal
adenocarcinoma and 7 (33.3%) for benign neoplasms (3 main-
duct intraductal papillary mucinous neoplasms [IPMNs], 2
mucinous cystic neoplasms [MCNs], 1 symptomatic serous
cystadenoma [SCA] and 1 chronic pancreatitis). 
The incidence of DGE (19%) was not statistically
different between the 2 groups: 3 in HBO group and 1 in
placebo group. There were 5 instances (23.8%) of
postoperative bleeding (3 in HBO group and 2 in placebo
group, PNS). One patient (placebo group) required
laparotomy 2 h after the initial surgery for common hepatic
artery repair. In the randomized patients, there were 6 POPF
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(28.6%) (2 type A, 2 type B and 2 type C sec. ISGPF), 3 in
the HBO group, 3 in the placebo group. There was one
biliary fistula (4.8%) in a patient of the placebo group.
Signiﬁcant differences in favor of HBO were found in
pulmonary complications (none in HBO group versus 6 in
placebo group; p=0.023).
In the patients that underwent PPPD, 6 pulmonary
infections were present, significantly less frequent in the
HBO group vs. placebo group (p=0.023), but were not
correlated with gender, histology, POPF, biliary fistula, fever,
use of antibiotics or age (Table II). There were 3 pulmonary
infections in males (50%) and 3 in females (50%). In 2 cases
(33.3%) pulmonary infections occurred in patients >65 years.
In 2 cases (33.3%), POPF and pulmonary infection were
present in the same patient and in 1 case (16.7%) the
pulmonary infection was present with biliary fistula. Use of
antibiotics was not significantly different between groups (4
in HBO group and 6 in placebo group, p=0.67) and the
incidence of fever was the same in the two groups (4 in HBO
group and 4 in sham group, p=1). 
Table III shows the correlation between gender, POPF,
biliary fistula, HBO, fever, DGE and the concentrations of
cytokines. IL-1 and TNF-α were correlated with fever
(p=0.006 and p=0.04 respectively). IL-6 was correlated with
biliary fistula and its concentration was affected by HBO
exposure, as was IL-10 (p=0.035). TNF-α was also
correlated with POPF (p=0.026). On the other hand, IL-8
and IL-12 were not influenced by HBO exposure (p=0.065
and p=0.69 respectively). 
The basal mean level of cytokines in patients with
unresectable pancreatic cancer was statistically different
from patients with resectable pancreatic cancer, especially
for IL-6 and IL-8 (p=0.0001 and p=0.046 respectively). 
Discussion
In the present study, we evaluated post-operative biological
and clinical effects of preoperative HBO in patients
undergoing pancreaticoduodenectomy. There were no
complications from the hyperbaric exposure in all patients. 
Pre-oxygenation studies. As already known, modulation of the
inflammatory response resulting from exposure to oxygen in a
hyperbaric chamber modifies the synthesis of growth factors
(VEGF) (1), reduces the concentration of pro-inflammatory
cytokines, and modulates tissue myeloperoxidase and
lipoperoxides (2).
During the reperfusion of ischemic tissue, oxygenated
blood increases number and activities of oxidants generated
in tissues. Reperfusion increases the hazardous effects of
early ischemic injury by release of cytokines and reactive
oxygen species (ROS) such as hydroxyl radical (OH¯),
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Figure 1. Flow-chart for randomization.
superoxide radical (O2¯), and hydrogen peroxide (H2O2) and
by the activation of complement system. This phenomenon
has been broadly named “ischemia-reperfusion (I/R) injury”.
Neural tissues as well as most visceral tissues can be all
involved in I/R, and animal models of different organs’
tolerance and vulnerability have been widely studied (39).
A critical role in ischemia-reperfusion injury is played by
TNF-α and IL-1β, as shown by Yang and Bosco (30-31) the
increased of TNF-α serum levels, occur in the early phase of
inflammation, whereas elevation of IL-1β levels occur in the
later phase, suggesting that this cytokine could sustain the
inflammation process. The same authors showed how an
ischemia-reperfusion injury could strike multiple organs:
increased TNF-α serum levels, sequel intestinal ischemia-
reperfusion injury, is responsible of acute lung injury (31). In
fact, TNF-α goes into the systemic circulation and is received
by resident population of macrophages in liver and lungs,
promoting the inflammation process also in other organs (33).
There exist many studies investigating I/R injury in
different tissues, such as kidney, liver, lung, testis, brain,
heart muscle, and skeletal muscle in the literature (34). I/R
injury in skeletal muscles (32) and also in bone may also
occur with vascular problems, including atherosclerotic
occlusive disease, arterial thrombosis, or arterial embolism,
after organ transplantation, cardiovascular surgery, and
vascular trauma (35). In addition, limb ischemia-reperfusion
occurs often in surgical procedures, when using a tourniquet
to provide a bloodless surgical field (32, 35). Although
hyperbaric oxygen (HBO) causes oxidative stress (36, 37)
similar to ischemic-preconditioning (PC), HBO-PC generates
a non-lethal level of ROS, which induces ischemic tolerance
and has protective effect after severe ischemic attacks (37,
38). Certain studies have shown that HBO-PC reduces I/R
damage by its antioxidant effect, hyperoxygenation, and
vasoconstriction. Furthermore, HBO is believed to exert its
antioxidant effect by reducing leucocyte recruitment and
activation, edema, cellular necrosis, and increasing the
efficacy of antioxidant enzymes (32, 36, 37). 
Despite improvements in surgical techniques and in
anesthetic management, ischemia-reperfusion injury remains
an inevitable event of cardiac surgery, resulting in significant
postoperative complications and multiple-organ dysfunction.
To date, brain injury after cardio-pulmonary bypass (CPB) for
cardiac surgery has been well-documented. Sequelae can be
as mild as postoperative cognitive dysfunction and
postoperative delirium and as severe as stroke (40). The
etiology of cerebral injuries is probably multi-factorial, from
an interaction among cerebral microemboli, global cerebral
hypoperfusion, inflammation, cerebral temperature modulation
and genetic susceptibility (41). Ischemia-reperfusion injury
during CPB also leads to myocardial stunning, necrosis, or
apoptosis that manifest clinically either acutely as low cardiac
output or chronically as heart failure (42).
Preconditioning is the application of an intervention to
activate endogenous protective mechanisms to reduce the
morphological and functional sequelae of a subsequent ischemia
insult. The phenomenon of ischemic preconditioning was first
described in a canine myocardium ischemia-reperfusion injury
model (43) and subsequently was shown in the brain (44). Since
then, intense research in the field of pharmacology ensued to
identify agents such as volatile anesthetic agents and ischemic
preconditioning (45-47) that could duplicate the protective
effects of preconditioning for cardiac surgery.
Despite the increasing number of basic science
publications on this issue, studies describing HBO
preconditioning in the clinical practice of general surgery
remain scarce. To date, only a few studies have investigated
the preconditioning effects of HBO in the human brain and
myocardium (48). In 2004 Sharifi et al. described the use of
HBO to inhibit restenosis after PTCI in acute myocardial
ANTICANCER RESEARCH 34: 2899-2906 (2014)
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Table I. Wilcoxon matched pairs test between HBO and placebo conditions for IL-1, IL-6, IL-8, IL-10, IL-12, TNF measure at T0, T1, T2, T3.
IL-1 IL-1 p-Value IL-6 IL-6 p-Value IL-8 IL-8 p-Value
(HBO) (placebo) (HBO) (placebo) (HBO) (placebo)
T0 0.41 0.47 0.196 5.06 5.97 0.009 15.95 15.77 0.71
T1 0.51 0.74 5.81 24.06 22.6 25.14
T2 1.4 1.35 141.23 179.54 38.05 37.54
T3 1.04 1.69 21.76 24.5 16.88 16.62
IL-10 IL-10 p-Value IL-12 IL-12 p-Value TNF TNF p-Value
(HBO) (placebo) (HBO) (placebo) (HBO) (placebo)
T0 2.01 4.04 0.034 0.46 0.41 0.8 0.38 0.4 0.18
T1 2.41 4.43 0.65 2.41 1 1.3
T2 5.6 7.76 0.59 0.11 0.73 0.61
T3 3.34 4.14 0.67 0.6 1.04 1.1
infarction (49). In 2005, Alex et al. observed that repetitive
pre-treatment with three sessions of HBO at 2.4 ATA before
on-pump coronary artery bypass graft (CABG) surgery
reduced neuropsychometric dysfunction and modulated
favorably the inflammatory response after CPB (16).
Yogaratnam et al. reported that preconditioning with a single
session of HBO at 2.5 ATA before on-pump CABG surgery
improved left ventricular stroke work post-CABG surgery
while reducing intraoperative blood loss, intensive care unit
(ICU) length of stay, and postoperative complications (17).
Recently, Li et al. aimed to determine whether HBO
preconditioning could decrease the release of cerebral and
myocardial biochemical markers. Endpoints of this study
included serum troponin I, inotrope usage, ventilator hours,
length of ICU stay, postoperative length of hospital stay,
hemodynamic parameters, and serum CAT activity (37). 
In conclusion, in this randomized pilot study for 32
patients selected using geographical criteria affected by
pancreatic cancer, several novel findings came to light, as for
the first time we evaluated the biological and clinical effects
of HBO in patients undergoing pancreatic surgery. 
Biological effects in our patients. The preoperative
hyperbaric therapy modulates the levels of IL-6 (p=0.009)
and IL-10 (p=0.03). It also seems that there is a statistically
significant relationship between IL-6 and biliary fistula
(p=0.009). IL-1 (p=0.006) and TNF-α (p=0.04) are
correlated with the hyperpyrexia and, in addition, TNF-α
should be in relation with the POPF (p=0.019). The
relationship of IL-1 with hyperbaric therapy has been
demonstrated only in orthopedic surgery (18) and in perianal
Crohn’s disease treatment by Weisz et al. (26). 
In the present study we found a relationship between HBO
exposure and the modulation of the level of IL-6 and IL-10
with a relationship between IL-6 and biliary fistula, IL-1 and
fever and a doubtful correlation between TNF- α and POPF.
Preoperative HBO action significantly decreased serum
concentration of IL-6 (p=0.009). In addition, we observed a
correlation between the occurrence of biliary fistula and
serum level of IL-6 (p=0.04).
Patients with unresectable tumors with metastasis (Stage IV
sec. AJCC) or with infiltration of adjacent structures (stage III
sec. AJCC) had a higher level of interleukins than resectable
patients. This difference is very marked as regards the IL-6
(p=0.0001, resectable vs. unresectable) and conceivably could
play a role in determining tumor staging. This relationship was
already suggested by Okisu et al. (27) that also observed that
the interaction with androgens receptors’ and the cytokine
concentration were in relation with mortality. Talar-
Wojnarowska et al. demonstrated that elevated levels of IL-6
could be related to a high metastatic potential through the
stimulation of growth factors, including VEGF (28). Pini et al.
confirmed it in mice pretreated with anti-IL-6 antibodies that
it participates in delayed recovery from acute inflammation
and may favor development of a pro-tumorigenic environment
through prolonged activation of STAT-3, induction of MMP-7
and sustained production of chemokines (50). Boreddy et al.
demonstrated that IL-6 drastically increased the expression of
HIF-1α (hypoxia inducible factor) and VEGF expression that
play a crucial role in pancreatic cancer progression (51).
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Table II. Correlation between age, histology, POPF, biliary fistula, fever,
postoperative antibiotics use, pulmonary complications, DGE, bleeding
and HBO exposition. 
HBO (N=10) Placebo (N=11) p-Value
Age (HBO - placebo )
M (5-4) 62.8±11.1 62.6±12.6 n.s.
F (5-7) 69±3.3 72.2±4.2
Histology
Benign 3 4 n.s.
Cancer 7 7
POPF
No 7 8 n.s.
Yes 3 3
Biliary fisula
No 10 10 n.s.
Yes 0 1
Fever
No 6 7 n.s.
Yes 4 4
Antibiotics
No 6 5 n.s.
Yes 4 6
Pulmonary complications
No 10 5 0.023
Yes 0 6
DGE
No 7 10 n.s.
Yes 3 1
Bleeding
No 7 9 n.s.
Yes 3 2
ns: Not significant.
Table III. Correlation between gender, POPF, biliary fistula, HBO, fever,
DGE and the concentrations of cytokines.
Gender POPF Biliary HBO Fever DGE
fistula
IL-1 n.s. n.s. n.s. n.s. 0.006 n.s.
IL-6 n.s. n.s. 0.04 0.009 n.s. n.s.
IL-8 n.s. n.s. n.s. n.s. n.s. n.s.
IL-10 n.s. n.s. n.s. 0.03 n.s. n.s.
IL-12 n.s. n.s. n.s. n.s. n.s. n.s.
TNF-α n.s. 0.019 n.s. n.s. 0.04 n.s.
ns: Not significant.
On the other hand, in a recent article, Grote et al.
demonstrated that IL-6 does not seem to have a role with
respect to risk of pancreatic cancer (52). 
IL-10 is an anti-inflammatory cytokine with protective
activity, its post-operative serum concentration results are
higher in patients who underwent HBO (p=0.03), such as
literature showed (29). In 2011, Ribatti et al. (53)
demonstrated that through the secretion of
immunosuppressive cytokines such as IL-10, mast cells
down-regulate the immune response to tumors. Mast cells,
in fact, produce and secrete potent angiogenic molecules, and
have been implicated in angiogenesis in various
malignancies, including laryngeal squamous cell carcinomas,
lung cancers and malignant melanomas (54).
The levels of IL-8, IL-10 and TNF-α were not modulated
by HBO.
Clinical effects in our patients. We found a relationship
between the different clinical variables and cytokines such
as the correlation between fever and IL-1 and TNF-α and the
pancreatic fistula with only TNF-α. Patients who underwent
a hyperbaric therapy session expressed a reduction in
postoperative pulmonary infections (p=0.023 vs. placebo)
but this effect was not associated with a statistically
significant decrease in the length of hospital stay (p=0.063),
fever (p=0.146) or use of antibiotics (p=0.063). The
occurrence of POPF can’t be explained only by an altered
inflammatory state (23-25) so the modulation of the
inflammatory response has only a marginal role (p=1). In
fact, the risk of POPF formation has been shown to be
directly proportional to the consistency of the residual organ
by virtually all authors (55-63) and is further supported by
the fact that anastomosis performed on chronic pancreatitis
patients with ﬁbrotic glands has a signiﬁcantly reduced
clinical incidence of complications related to anastomosis
(64). In conclusion, the preoperative exposure to hyperbaric
environment is safe and can be applied to all patients after
careful clinical evaluation and identification of absolute
contraindications as per chemotherapic protocol (65). 
IL-6 expression in these cases is usually increased and
particularly related with the biliary fistula, but shows itself
to be sharply influenced under hyperbaric oxygen exposure
conditions. This may suggest a potential HBO in decreasing
the incidence of postoperative biliary fistulas and pneumonia.
Moreover this cytokine may be useful as a prognostic marker
or indicator of disease progression. Maybe it is possible that
high basal levels of IL-6 may be related to the presence of a
tumor in advanced stage and therefore the patient is
candidabile to neoadjuvant treatment.
In conclusion, in this pilot randomized study we found
that a single preoperative HBO session the day before
pancreatic surgery should modulate the inflammatory
response, especially for IL-6 and IL-10 with a decrease in
postoperative pneumonia. Further studies are required to
evaluate the response to HBO in a larger number of patients
and in other surgical procedures, especially major surgeries
leading to postoperative ICU admission.
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